Trials / Completed
CompletedNCT04991935
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-93538 | CC-93538 |
Timeline
- Start date
- 2022-08-09
- Primary completion
- 2025-08-14
- Completion
- 2025-08-14
- First posted
- 2021-08-05
- Last updated
- 2026-04-06
- Results posted
- 2026-04-06
Locations
167 sites across 15 countries: United States, Argentina, Australia, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04991935. Inclusion in this directory is not an endorsement.